Mohamed W Attwa

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2944328/publications.pdf

Version: 2024-02-01

69 papers	1,115 citations	279487 23 h-index	476904 29 g-index
71 all docs	71 docs citations	71 times ranked	591 citing authors

#	Article	IF	Citations
1	Isatin-benzoazine molecular hybrids as potential antiproliferative agents: synthesis and in vitro pharmacological profiling. Drug Design, Development and Therapy, 2017, Volume 11, 2333-2346.	2.0	50
2	An LCâ€“MS/MS method for rapid and sensitive highâ€throughput simultaneous determination of various protein kinase inhibitors in human plasma. Biomedical Chromatography, 2017, 31, e3793.	0.8	41
3	Investigation of metabolic degradation of new ALK inhibitor: Entrectinib by LC-MS/MS. Clinica Chimica Acta, 2018, 485, 298-304.	0.5	38
4	Metabolic Stability Assessment of New PARP Inhibitor Talazoparib Using Validated LCâ€“MS/MS Methodology: In silico Metabolic Vulnerability and Toxicity Studies . Drug Design, Development and Therapy, 2020, Volume 14, 783-793.	2.0	38
5	LCâ€“MS/MS reveals the formation of iminium and quinone methide reactive intermediates in entrectinib metabolism: In vivo and in vitro metabolic investigation. Journal of Pharmaceutical and Biomedical Analysis, 2018, 160, 19-30.	1.4	37
6	Reactive intermediates and bioactivation pathways characterization of avitinib by LCâ€“MS/MS: In vitro metabolic investigation. Journal of Pharmaceutical and Biomedical Analysis, 2019, 164, 659-667.	1.4	37
7	Identification and characterization of in vitro phase I and reactive metabolites of masitinib using a LC-MS/MS method: bioactivation pathway elucidation. RSC Advances, 2017, 7, 4479-4491.	1.7	35
8	Detection and characterization of ponatinib reactive metabolites by liquid chromatography tandem mass spectrometry and elucidation of bioactivation pathways. RSC Advances, 2016, 6, 72575-72585.	1.7	34
9	Identification and characterization of in vivo, in vitro and reactive metabolites of vandetanib using LCâ€“ESIâ€“MS/MS. Chemistry Central Journal, 2018, 12, 99.	2.6	33
10	LC-MS/MS reveals the formation of aldehydes and iminium reactive intermediates in foretinib metabolism: phase I metabolic profiling. RSC Advances, 2017, 7, 36279-36287.	1.7	31
11	A reliable and stable method for the determination of foretinib in human plasma by LC-MS/MS: Application to metabolic stability investigation and excretion rate. European Journal of Mass Spectrometry, 2018, 24, 344-351.	0.5	31
12	Phase I metabolic profiling and unexpected reactive metabolites in human liver microsome incubations of X-376 using LC-MS/MS: bioactivation pathway elucidation andin silicotoxicity studies of its metabolites. RSC Advances, 2020, 10, 5412-5427.	1.7	31
13	LCâ€“MS/MS method for the quantification of masitinib in RLMs matrix and rat urine: application to metabolic stability and excretion rate. Chemistry Central Journal, 2017, 11, 136.	2.6	30
14	Validated LC-MS/MS Method for the Quantification of Ponatinib in Plasma: Application to Metabolic Stability. PLoS ONE, 2016, 11, e0164967.	1.1	29
15	Identification and characterization of in silico, in vivo, in vitro, and reactive metabolites of infigratinib using LC-ITMS: bioactivation pathway elucidation and in silico toxicity studies of its metabolites. RSC Advances, 2020, 10, 16231-16244.	1.7	29
16	A highly efficient and sensitive LCâ€MS/MS method for the determination of afatinib in human plasma: application to a metabolic stability study. Biomedical Chromatography, 2016, 30, 1248-1255.	0.8	28
17	Liquid chromatography tandem mass spectrometry method for the quantification of vandetanib in human plasma and rat liver microsomes matrices: metabolic stability investigation. Chemistry Central Journal, 2017, 11, 45.	2.6	28
18	LC-ESI-MS/MS reveals the formation of reactive intermediates in brigatinib metabolism: elucidation of bioactivation pathways. RSC Advances, 2018, 8, 1182-1190.	1.7	28

#	Article	IF	Citations
19	Investigation of the metabolic stability of olmutinib by validated LC-MS/MS: quantification in human plasma. RSC Advances, 2018, 8, 40387-40394.	1.7	28
20	Detection and characterization of olmutinib reactive metabolites by LCâ€“MS/MS: Elucidation of bioactivation pathways. Journal of Separation Science, 2020, 43, 708-718.	1.3	28
21	Investigation of metabolic stability of the novel ALK inhibitor brigatinib by liquid chromatography tandem mass spectrometry. Clinica Chimica Acta, 2018, 480, 180-185.	0.5	27
22	LC-MS/MS reveals the formation of reactive ortho -quinone and iminium intermediates in saracatinib metabolism: Phase I metabolic profiling. Clinica Chimica Acta, 2018, 482, 84-94.	0.5	25
23	Liquid chromatographic-tandem mass spectrometric assay for simultaneous quantitation of tofacitinib, cabozantinib and afatinib in human plasma and urine. Tropical Journal of Pharmaceutical Research, 2017, 15, 2683.	0.2	24
24	Identification of reactive intermediate formation and bioactivation pathways in Abemaciclib metabolism by LCâ€“MS/MS: in vitro metabolic investigation. Royal Society Open Science, 2019, 6, 181714.	1.1	24
25	Validated LC-MS/MS assay for quantification of the newly approved tyrosine kinase inhibitor, dacomitinib, and application to investigating its metabolic stability. PLoS ONE, 2019, 14, e0214598.	1.1	22
26	EGFR Inhibitor Gefitinib Induces Cardiotoxicity through the Modulation of Cardiac PTEN/Akt/FoxO3a Pathway and Reactive Metabolites Formation: In Vivo and in Vitro Rat Studies. Chemical Research in Toxicology, 2020, 33, 1719-1728.	1.7	22
27	A simple liquid chromatography-tandem mass spectrometry method to accurately determine the novel third-generation EGFR-TKI naquotinib with its applicability to metabolic stability assessment. RSC Advances, 2019, 9, 4862-4869.	1.7	21
28	High Throughput Quantitative Bioanalytical LC/MS/MS Determination of Gemifloxacin in Human Urine. Journal of Chemistry, 2013, 2013, 1-9.	0.9	16
29	In silico and in vitro metabolism of ribociclib: a mass spectrometric approach to bioactivation pathway elucidation and metabolite profiling. RSC Advances, 2020, 10, 22668-22683.	1.7	16
30	Characterization of reactive intermediates formation in dacomitinib metabolism and bioactivation pathways elucidation by LC-MS/MS: in vitro phase I metabolic investigation. RSC Advances, 2018, 8, 38733-38744.	1.7	14
31	A highly sensitive LC-MS/MS method to determine novel Bruton's tyrosine kinase inhibitor spebrutinib: application to metabolic stability evaluation. Royal Society Open Science, 2019, 6, 190434.	1.1	14
32	Rapid validated liquid chromatographic method coupled with Tandem mass spectrometry for quantification of nintedanib in human plasma. Tropical Journal of Pharmaceutical Research, 2016, 15, 2467.	0.2	13
33	Belizatinib: Novel reactive intermediates and bioactivation pathways characterized by LCâ€“MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2019, 171, 132-147.	1.4	13
34	Identification of Iminium Intermediates Generation in the Metabolism of Tepotinib Using LC-MS/MS: In Silico and Practical Approaches to Bioactivation Pathway Elucidation. Molecules, 2020, 25, 5004.	1.7	12
35	Development and validation of an HPLC-MS/MS method for the determination of filgotinib, a selective Janus kinase 1 inhibitor: Application to a metabolic stability study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2020, 1154, 122195.	1.2	12
36	LC-MS/MS method for the quantification of the anti-cancer agent infigratinib: Application for estimation of metabolic stability in human liver microsomes. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1179, 122806.	1.2	10

#	Article	IF	Citations
37	Microwave-Assisted Solution-Phase Synthesis and DART-Mass Spectrometric Monitoring of a Combinatorial Library of Indolin-2,3-dione Schiff Bases with Potential Antimycobacterial Activity. Molecules, 2011, 16, 5194-5206.	1.7	9
38	Development of novel univariate and multivariate validated chemometric methods for the analysis of dasatinib, sorafenib, and vandetanib in pure form, dosage forms and biological fluids. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2022, 264, 120336.	2.0	8
39	Fragmentation Behavior Studies of Chalcones Employing Direct Analysis in Real Time (DART). Mass Spectrometry Letters, 2013, 4, 30-33.	0.5	8
40	A validated LC-MS/MS analytical method for the quantification of pemigatinib: metabolic stability evaluation in human liver microsomes. RSC Advances, 2022, 12, 20387-20394.	1.7	8
41	Induced in-source fragmentation pattern of certain novel (1Z,2E)-N-(aryl)propanehydrazonoyl chlorides by electrospray mass spectrometry (ESI-MS/MS). Chemistry Central Journal, 2013, 7, 16.	2.6	7
42	A Preliminary Study of Arecoline and Guvacoline Presence in the Saliva of a â€œBetel-Quidâ€•Chewer Using Liquid-Chromatography Ion Trap Mass Spectrometry. European Journal of Mass Spectrometry, 2013, 19, 391-397.	0.5	7
43	LC-ESI-MS/MS identification and characterization of ponatinib in vivo phase I and phase II metabolites. Clinica Chimica Acta, 2018, 485, 144-151.	0.5	7
44	Validated liquid chromatography tandem mass spectrometry for simultaneous quantification of foretinib and lapatinib, and application to metabolic stability investigation. RSC Advances, 2019, 9, 19325-19332.	1.7	7
45	A Validated LCâ€“MS/MS Assay for the Simultaneous Quantification of the FDA-Approved Anticancer Mixture (Encorafenib and Binimetinib): Metabolic Stability Estimation. Molecules, 2021, 26, 2717.	1.7	7
46	Simple and efficient spectroscopic-based univariate sequential methods for simultaneous quantitative analysis of vandetanib, dasatinib, and sorafenib in pharmaceutical preparations and biological fluids. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2021, 260, 119987.	2.0	7
47	Exploring the effect of khat (Catha edulis) chewing on the pharmacokinetics of the antiplatelet drug clopidogrel in rats using the newly developed LC-MS/MS technique. Open Chemistry, 2020, 18, 681-690.	1.0	7
48	Estimation of zorifertinib metabolic stability in human liver microsomes using LCâ€“MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2022, 211, 114626.	1.4	7
49	Development and validation of HPLCâ€MS/MS method for the determination of lixivaptan in mouse plasma and its application in a pharmacokinetic study. Biomedical Chromatography, 2017, 31, e4007.	0.8	6
50	Development and validation of an HPLCâ€“MS/MS method for the determination of arginine-vasopressin receptor blocker conivaptan in human plasma and rat liver microsomes: application to a metabolic stability study. Chemistry Central Journal, 2018, 12, 47.	2.6	6
51	Reactive intermediates in copanlisib metabolism identified by LC-MS/MS: phase I metabolic profiling. RSC Advances, 2019, 9, 6409-6418.	1.7	6
52	Identification and characterization of in vitro, in vivo, and reactive metabolites of tandutinib using liquid chromatography ion trap mass spectrometry. Analytical Methods, 2021, 13, 399-410.	1.3	6
53	Effective quantification of ravidasvir (an NS5A inhibitor) and sofosbuvir in rat plasma by validated LC-MS/MS method and its application to pharmacokinetic study. Arabian Journal of Chemistry, 2020, 13, 8160-8171.	2.3	5
54	Characterization of in vivo metabolites in rat urine following an oral dose of masitinib by liquid chromatography tandem mass spectrometry. Chemistry Central Journal, 2018, 12, 61.	2.6	4

#	Article	IF	Citations
55	Sapitinib: reactive intermediates and bioactivation pathways characterized by LC-MS/MS. RSC Advances, 2019, 9, 32995-33006.	1.7	4
56	LC-MS/MS Estimation of the Anti-Cancer Agent Tandutinib Levels in Human Liver Microsomes: Metabolic Stability Evaluation Assay . Drug Design, Development and Therapy, 2020, Volume 14, 4439-4449.	2.0	4
57	Metabolic Stability Assessment of Larotrectinib Using Liquid Chromatography Tandem Mass Spectrometry . Drug Design, Development and Therapy, 2020, Volume 14, 111-119.	2.0	4
58	A New Validated HPLC-MS/MS Method for Quantification and Pharmacokinetic Evaluation of Dovitinib, a Multi-Kinase Inhibitor, in Mouse Plasma . Drug Design, Development and Therapy, 2020, Volume 14, 407-415.	2.0	4
59	Spectroscopic, molecular docking and dynamic simulation studies of binding between the new anticancer agent olmutinib and human serum albumin. Journal of Biomolecular Structure and Dynamics, 2022, 40, 14236-14246.	2.0	4
60	Pseudo-MS3Approach Using Electrospray Mass Spectrometry (ESI-MS/MS) to Characterize Certain (2E)-2-[3-(1H-Imidazol-1-yl)-1-phenylpropylidene]hydrazinecarboxamide Derivatives. Journal of Chemistry, 2014, 2014, 1-10.	0.9	3
61	Liquid chromatographic-mass spectrometric method for determination of drug content uniformity of two commonly used dermatology medications in a split-tablet dosage form. Tropical Journal of Pharmaceutical Research, 2016, 15, 1283.	0.2	3
62	Liquid chromatographyâ€“tandem mass spectrometry metabolic profiling of nazartinib reveals the formation of unexpected reactive metabolites. Royal Society Open Science, 2019, 6, 190852.	1.1	3
63	Characterization of Stable and Reactive Metabolites of the Anticancer Drug, Ensartinib, in Human Liver Microsomes Using LC-MS/MS: An in silico and Practical Bioactivation Approach . Drug Design, Development and Therapy, 2020, Volume 14, 5259-5273.	2.0	3
64	Detection and characterization of simvastatin and its metabolites in rat tissues and biological fluids using MALDI high resolution mass spectrometry approach. Scientific Reports, 2022, 12, 4757.	1.6	3
65	Multistage Fragmentation of Ion Trap Mass Spectrometry System and Pseudo-MS³of Triple Quadrupole Mass Spectrometry Characterize Certain (E)-3-(Dimethylamino)-1-arylprop-2-en-1-ones: A Comparative Study. Scientific World Journal, The, 2014, 2014, 1-9.	0.8	2
66	Reactive intermediates in naquotinib metabolism identified by liquid chromatography-tandem mass spectrometry: phase I metabolic profiling. RSC Advances, 2019, 9, 10211-10225.	1.7	2
67	LCâ€“MS/MS Estimation of Rociletinib Levels in Human Liver Microsomes: Application to Metabolic Stability Estimation. Drug Design, Development and Therapy, 2021, Volume 15, 3915-3925.	2.0	2
68	Fragmentation pattern of certain isatinâ€“indole antiproliferative conjugates with application to identify their in vitro metabolic profiles in rat liver microsomes by liquid chromatography tandem mass spectrometry. Open Chemistry, 2020, 18, 503-515.	1.0	2
69	Lodenafil. Profiles of Drug Substances, Excipients and Related Methodology, 2022, 47, 113-147.	3.5	1